CNDRF collaboration. Global trends in body mass index, underweight, overweight and obesity from 1975 to 2016: a pooled analysis of 2,416 population-based measurement studies involving 128.9 million children , teenagers and adults. Lancet. 2017;390:2627–42.
Hales CM, Fryar CD, Carroll MD, Freedman DS, Ogden CL. Trends in the prevalence of obesity and severe obesity among American youth and adults by sex and age, 2007-2008 to 2015-2016. JAMA. 2018;319:1723–5.
Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and risk of heart failure. N Engl J Med. 2002;347:305–13.
Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, et al. Body mass index, abdominal adiposity, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Traffic. 2016;133:639–49.
By Maria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176–83.
Sjostrom L. Review of the main results of the Swedish trial in obese subjects (SOS) – a prospective controlled intervention study of bariatric surgery. J Med Intern. 2013;273:219–34.
Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang WY, Zhang ZY, et al. Risk of incident heart failure: a subject-level meta-analysis from the OMics Heart Aging (HOMAGE) Study. J Am Heart Assoc. 2017;6.
Sahle BW, Owen AJ, Chin KL, Reid CM. Models for predicting incident heart failure risk: a systematic review of model methodology and performance. Failed Map J. 2017;23:680–7.
Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422:193–7.
Singla P, Bardoloi A, Parkash AA. Metabolic effects of obesity: a review. World J Diabetes. 2010;1:76–88.
Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, assessment, and effect of weight loss: an update of the American Heart Association’s 1997 scientific statement on obesity and heart disease from the Obesity Committee of the Council on the nutrition, physical activity and metabolism. Traffic. 2006;113:898–918.
Sjostrom L, Larsson B, Backman L, Bengtsson C, Bouchard C, Dahlgren S, et al. Swedish Obese Subjects (SOS). Recruitment for an interventional study and a selective description of the obese state. Int J Obesity. 1992;16:465–79.
Essebag V, Genest Jr., Suissa S, Pilote L. The case-control study nested in cardiology. Am Heart J. 2003;146:581–90.
Hsieh FY, Bloch DA, Larsen MD. A simple method of calculating sample size for linear and logistic regression. StatMed. 1998;17:1623–34.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR Stat Soc. 1995;57:289–300.
Kamburov A, Stelzl U, Lehrach H, Herwig R. The ConsensusPathDB Interaction Database: 2013 Update. Nucleic Acids Res. 2013;41:D793–800.
Greenland S. Interaction tests in epidemiological studies: a review and power study. StatMed. 1983;2:243–51.
Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyzes in randomized trials: risks of subgroup-specific analyses; the power and sample size for the interaction test. J Clin Epidemiol. 2004;57:229–36.
Schwenk RW, Vogel H, Schurmann A. Genetic and epigenetic control of metabolic health. Mol Metab. 2013;2:337–47.
Xu S, Lind L, Zhao L, Lindahl B, Venge P. Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and linked to cardiovascular dysfunction. Clin Chem. 2012;58:1110–5.
Micheau O Regulation of ligand signaling inducing TNF-related apoptosis by glycosylation. Int J Mol Sci. 2018;19.
Hanasaki K, Varki A, Stamenkovic I, Bevilacqua MP. Cytokine-induced beta-galactoside alpha-2,6-sialyltransferase in human endothelial cells mediates alpha 2,6-sialylation of CD22 adhesion molecules and ligands. J Biol Chem. 1994;269:10637–43.
Kosmala W, Plaksej R, Przewlocka-Kosmala M, Kuliczkowska-Plaksej J, Bednarek-Tupikowska G, Mazurek W. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship with cardiac function. Int J Obes. 2008; 32: 763–71.
Cynis H, Hoffmann T, Friedrich D, Kehlen A, Gans K, Kleinschmidt M, et al. The glutaminyl cyclase isoenzyme is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol Med. 2011;3:545–58.
Zhu R, Liu C, Tang H, Zeng Q, Wang X, Zhu Z, et al. Serum galectin-9 levels are associated with coronary heart disease in Chinese individuals. Inflamm. Mediators 2015;2015:457167.
Suzuki K. The multifunctional serpin, protein C inhibitor: beyond thrombosis and hemostasis. J Thromb Haemost. 2008;6:2017–26.
Ruge T, Carlsson AC, Ingelsson E, Riserus U, Sundstrom J, Larsson A, et al. Circulating endostatin and the incidence of heart failure. Scand Cardiovascular J. 2018;52:244–9.
Stenemo M, Nowak C, Byberg L, Sundstrom J, Giedraitis V, Lind L, et al. Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart failure. 2018;20:55–62.
Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJ, et al. Lipoprotein lipase S447X: a natural gain-of-function mutation. Arterioscler Thromb Vasc Biol. 2006;26:1236–45.
Bjorkbacka H, Yao Mattisson I, Wigren M, Melander O, Fredrikson GN, Bengtsson E, et al. Plasma stem cell factor levels are associated with the risk of cardiovascular disease and death. J Med Intern. 2017;282:508–21.
Yang H, Geiger M. Cell penetrating SERPINA5 (protein C inhibitor, PCI): more questions than answers. Semin Cell Dev Biol. 2017;62:187–93.
Carroll VA, Griffiths MR, Geiger M, Merlo C, Furlan M, Lammle B, et al. Plasma protein C inhibitor is elevated in myocardial infarction survivors. Arterioscler Thromb Vasc Biol. 1997;17:114–8.
Wang XQ, Liu ZH, Xue L, Lu L, Gao J, Shen Y, et al. C1q/TNF-related protein 1 links macrophage lipid metabolism to inflammation and atherosclerosis. Atherosclerosis. 2016;250:38–45.
Wang H, Wang R, Du D, Li F, Li Y. Serum levels of C1q/TNF-related protein-1 (CTRP-1) are strongly associated with coronary artery disease. BMC cardiovascular disorder. 2016;16:92.
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest. 2005;115:1627–35.
Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a condition resistant to fibroblast growth factor 21 (FGF21). Diabetic sugar. 2010;59:2781–9.
Dupont M, Wu Y, Hazen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk of adverse cardiovascular events. Cardiac failure Circ. 2012;5:602–9.
Shulman A, Peltonen M, Sjostrom CD, Andersson-Assarsson JC, Taube M, Sjoholm K, et al. Incidence of end-stage renal disease after bariatric surgery in the Swedish study on obese subjects. Int J Obes (London). 2018;42:964–73.
Rothberg AE, McEwen LN, Herman WH. Severe obesity and the impact of medical weight loss on estimated glomerular filtration rate. PLoS One. 2020;15:e0228984.
Levey AS, Schoolwerth AC, Burrows NR, Williams DE, Stith KR, McClellan W, et al. Comprehensive public health strategies to prevent the development, progression, and complications of CKD: report of an expert panel convened by the Centers for Disease Control and Prevention. Am J Kidney Dis. 2009;53:522–35.
Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, et al. Cardiac and renal benefits of empagliflozin in heart failure across the spectrum of renal function: insights from EMPEROR-Reduced. Traffic. 2021;143:310–21.
Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart failure. 2005;7:787–91.
Register of causes of death 2018 [Available from: http://www.socialstyrelsen.se/statistics/statisticaldatabase/help/causeofdeath].
Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, et al. Homogeneous PEA 96-plex immunoassay with high sensitivity, specificity and excellent scalability. PLoS One. 2014;9:e95192.